SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cell MedX Corp. – ‘NT 10-K’ for 5/31/22

On:  Monday, 8/29/22, at 4:11pm ET   ·   Effective:  8/29/22   ·   For:  5/31/22   ·   Accession #:  1393905-22-324   ·   File #:  0-54500

Previous ‘NT 10-K’:  ‘NT 10-K’ on 8/31/20 for 5/31/20   ·   Next & Latest:  ‘NT 10-K’ on 8/29/23 for 5/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/29/22  Cell MedX Corp.                   NT 10-K     5/31/22    1:18K                                    Empire Stock Transf… Inc

Notice of a Late Filing of a Form 10-K Annual Report   —   Form 12b-25   —   Rule 12b-25

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NT 10-K     Form 12B-25                                         HTML     17K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 
  Form 12b-25  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER

000-54500

CUSIP NUMBER

15115X 107

 

(Check One):

Form 10-K Form 20-F Form 11-K Form 10-Q   Form 10-D Form N-SAR   Form N-CSR

 

For Period Ended:May 31, 2022 

 

 Transition Report on Form 10-K

 Transition Report on Form 20-F

 Transition Report on Form 11-K

 Transition Report on Form 10-Q

 Transition Report on Form N-SAR

For the Transition Period Ended:  ________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I - REGISTRANT INFORMATION

 

CELL MEDX CORP.

Full Name of Registrant

 

Not Applicable

Former Name, If Applicable

 

123 W. NYE LN, SUITE 446

Address of Principal Executive Office (Street and Number)

 

CARSON CITY NV 89706

City, State and Zip Code

 

PART II - RULES 12B-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box, if appropriate)

 

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

(b) The subject annual report, semi-annual report, transition report on Form 10-K,  Form 20-F,  Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.


PART III - NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be file within the prescribed time period.

 

Cell MedX Corp. was unable to prepare the financial and business information necessary to file its Annual Report on Form 10-K by the prescribed due date without unreasonable effort or expense.  Cell MedX Corp. expects to be able to file its Annual Report on Form 10-K within 15 calendar days of the prescribed due date.

 

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contract in regard to this notification. 

 

Dwayne Yaretz

 

(844)

 

238-2692

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If the answer is no, identify report(s). 

Yes   No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? 

Yes   No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

 

 

 

 

 

 

 

 

 


2


 

 

CELL MEDX CORP.

(Name of Registrant as specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Date:  August 29, 2022

By:  /s/ Dwayne Yaretz

Dwayne Yaretz

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


3


Dates Referenced Herein

This ‘NT 10-K’ Filing    Date    Other Filings
Filed on / Effective on:8/29/22None on these Dates
For Period end:5/31/22
 List all Filings 
Top
Filing Submission 0001393905-22-000324   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 10:21:13.1am ET